AstraZeneca's Vaccine Reach Expands with Icosavax Deal
AstraZeneca has agreed to acquire Icosavax for up to $1.1 billion, signaling a major expansion in its vaccine and infectious disease portfolio.
Charts and financial information provided by TradingView, a popular charting & trading platform. Check out even more advanced features or grab charts for your website.
All Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.
AstraZeneca has agreed to acquire Icosavax for up to $1.1 billion, signaling a major expansion in its vaccine and infectious disease portfolio.